89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

89bio said its drug was bet­ter than place­bo at less­en­ing fi­bro­sis with­out wors­en­ing non­al­co­holic steato­hep­ati­tis, or NASH, in two of three dose groups.

The San Fran­cis­co biotech said it thinks the Phase IIb da­ta pave the way for a po­ten­tial Phase III, fol­low­ing in the foot­steps of an­oth­er biotech in its drug class, Akero Ther­a­peu­tics. To fund a late-stage study, CEO Ro­han Palekar told End­points News 89bio “would need to raise ad­di­tion­al cap­i­tal,” with the com­pa­ny hav­ing about $188 mil­lion at the end of last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER